Skip to main content

bladder cancer

Real-World Survival Trends in Muscle-Invasive Bladder Cancer and Urothelial Carcinoma
Videos
03/12/2021
Nimira Alimohamed, MD, discusses results from a real-world analysis of outcomes over time in patients with muscle-invasive bladder cancer and patients with metastatic urothelial carcinoma.
Nimira Alimohamed, MD, discusses results from a real-world analysis of outcomes over time in patients with muscle-invasive bladder cancer and patients with metastatic urothelial carcinoma.
Nimira Alimohamed, MD, discusses...
03/12/2021
Journal of Clinical Pathways
The Real-World Lifetime Economic Burden of Urothelial Carcinoma by Stage at Diagnosis
Research Reports
05/19/2020
Abstract: Urothelial carcinoma (UC) is generally diagnosed early and may incur significant lifetime costs. This study estimated, from the payer’s perspective, the lifetime costs among patients diagnosed with UC...
Abstract: Urothelial carcinoma (UC) is generally diagnosed early and may incur significant lifetime costs. This study estimated, from the payer’s perspective, the lifetime costs among patients diagnosed with UC...
...
05/19/2020
Journal of Clinical Pathways
06/04/2017
JCP Editors
Neoadjuvant gemcitabine-based chemotherapy, followed by gemcitabine-based concomitant chemoradiation, may aid in bladder preservation for patients receiving treatment for muscle-invasive bladder cancer in...
Neoadjuvant gemcitabine-based chemotherapy, followed by gemcitabine-based concomitant chemoradiation, may aid in bladder preservation for patients receiving treatment for muscle-invasive bladder cancer in...
...
06/04/2017
Journal of Clinical Pathways
05/31/2017
JCP Editors
Few patients with metastatic urothelial carcinoma of the bladder are surviving as long in the real-world as those in clinical trials, according to new research. Current overall survival projections for patients with...
Few patients with metastatic urothelial carcinoma of the bladder are surviving as long in the real-world as those in clinical trials, according to new research. Current overall survival projections for patients with...
Few...
05/31/2017
Journal of Clinical Pathways
05/16/2017
JCP Editors
Recommended primary treatment for non-muscle invasive micropapillary urothelial carcinoma (MPBC) is often foregone in community cancer centers and academic centers, according to a study presented at the American...
Recommended primary treatment for non-muscle invasive micropapillary urothelial carcinoma (MPBC) is often foregone in community cancer centers and academic centers, according to a study presented at the American...
...
05/16/2017
Journal of Clinical Pathways
Research in Review
11/14/2016
JCP Editors
An anti-PD-1 therapy significantly improves overall survival (OS) compared with chemotherapy in previously treated patients with advanced bladder (urothelial) cancer, according to a study presented at the Society for...
An anti-PD-1 therapy significantly improves overall survival (OS) compared with chemotherapy in previously treated patients with advanced bladder (urothelial) cancer, according to a study presented at the Society for...
An...
11/14/2016
Journal of Clinical Pathways
06/07/2016
JCP Editors
Nivolumab may help to significantly reduce tumor burden in patients with metastatic bladder cancer, regardless of whether their tumors have a biomarker related to the drug’s target, according to clinical trial...
Nivolumab may help to significantly reduce tumor burden in patients with metastatic bladder cancer, regardless of whether their tumors have a biomarker related to the drug’s target, according to clinical trial...
...
06/07/2016
Journal of Clinical Pathways